Abstract 996P
Background
For unresectable hepatocellular carcinoma (uHCC), the efficacy of transarterial chemoembolization (TACE) monotherapy is not satisfactory. Some studies have shown that TACE combined with molecular targeted drugs and programmed death-1 (PD-1) inhibitors shows potential synergistic effects that can prolong the overall survival (OS) of patients with uHCC. Donafenib is a new generation of multi-kinase inhibitor which is approved as the first line treatment for uHCC. This study aimed to evaluate the efficacy and safety of TACE combined with donafenib plus PD-1 inhibitor (TACE+DP) and of TACE combined with donafenib (TACE+D) for uHCC in a multicenter retrospective study.
Methods
The clinical data of patients with uHCC who had received TACE+DP or TACE+D as first-line treatment from six Chinese academic centers, from July 2021 to July 2022, were collected and retrospectively analyzed. In the TACE+DP group, patients received intravenous administration of PD-1 inhibitor every three weeks and oral donafenib (0.2 g) twice daily until intolerable toxicity or disease progression. In the TACE+D group, patients received the same dose of donafenib 3-5 days after TACE. Overall survival (OS), progression-free survival (PFS), and tumor responses were evaluated between the two groups according to the modified RECIST criteria.
Results
A total of 157 patients in the TACE+D group and 166 patients in TACE+DP group were included in this study. Patients in the TACE+DP group had longer median OS (18.1 vs 13.2 months, P<0.001) and longer median PFS (10.6 vs 7.9 months, P<0.001) than those in the TACE+D group. Patients in the TACE+DP group achieved a higher ORR (50.6% vs 41.4%, P=0.019) and a higher disease control rate (DCR) (89.2% vs 82.8%, P=0.010) than those in the TACE+D group. There was no significant difference in the incidence and severity of adverse events in the TACE+DP and TACE+D groups (any grade, 92.9% vs. 94.6%, P=0.270; grade 3 or 4, 33.8% vs. 37.3%, P=0.253).
Conclusions
With favorable safety and tolerability, TACE combined donafenib with PD-1 inhibitors significantly improves PFS, OS, and ORR over TACE combined with donafenib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital of Zhengzhou University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18